Abstract
We evaluated the effects of the glycosaminoglycan sulodexide (SDX; antithrombotic/profibrinolytic drug) on the activity and release of matrix metalloproteinases (MMPs) in human blood. This was a prospective non-randomized study, analyzing by zymography and ELISA the in vitro effects of SDX on pro-enzyme, complexed, and active MMP forms in plasma and serum from 60 healthy donors, and in U-937 leukemia cell line. The levels and zymographic profile of MMP-2 did not show significant changes among samples and during SDX treatments. However, pro- and complexed forms of MMP-9 were strongly affected by SDX treatment (P<0.001), with significant decrease of MMP-9 secretion from white blood cells in a dose-dependent fashion (P<0.0001), without any displacement of MMP prodomains. The mechanism of reduced release of MMP-9 forms from leukocytes and inhibition of proteolytic activity due to SDX treatment may support the hypothesis that drugs based upon inhibitors of MMP-9 activity may provide a therapeutic tool for the underlying pathological destruction of extracellular matrix, and offering novel pharmacologic applications for chronic inflammatory vascular diseases, including varicose vein and chronic venous diseases associated with enhanced MMP activation in blood and limbs.
Keywords: Chronic venous disease, dermatan sulphate, glycosaminoglycan, matrix metalloproteinases, plasma, sulodexide, U937 cell line.
Current Vascular Pharmacology
Title:Glycosaminoglycan Sulodexide Inhibition of MMP-9 Gelatinase Secretion and Activity: Possible Pharmacological Role Against Collagen Degradation in Vascular Chronic Diseases
Volume: 11 Issue: 3
Author(s): Ferdinando Mannello, Virginia Medda, Daniela Ligi and Joseph D. Raffetto
Affiliation:
Keywords: Chronic venous disease, dermatan sulphate, glycosaminoglycan, matrix metalloproteinases, plasma, sulodexide, U937 cell line.
Abstract: We evaluated the effects of the glycosaminoglycan sulodexide (SDX; antithrombotic/profibrinolytic drug) on the activity and release of matrix metalloproteinases (MMPs) in human blood. This was a prospective non-randomized study, analyzing by zymography and ELISA the in vitro effects of SDX on pro-enzyme, complexed, and active MMP forms in plasma and serum from 60 healthy donors, and in U-937 leukemia cell line. The levels and zymographic profile of MMP-2 did not show significant changes among samples and during SDX treatments. However, pro- and complexed forms of MMP-9 were strongly affected by SDX treatment (P<0.001), with significant decrease of MMP-9 secretion from white blood cells in a dose-dependent fashion (P<0.0001), without any displacement of MMP prodomains. The mechanism of reduced release of MMP-9 forms from leukocytes and inhibition of proteolytic activity due to SDX treatment may support the hypothesis that drugs based upon inhibitors of MMP-9 activity may provide a therapeutic tool for the underlying pathological destruction of extracellular matrix, and offering novel pharmacologic applications for chronic inflammatory vascular diseases, including varicose vein and chronic venous diseases associated with enhanced MMP activation in blood and limbs.
Export Options
About this article
Cite this article as:
Mannello Ferdinando, Medda Virginia, Ligi Daniela and Raffetto Joseph D., Glycosaminoglycan Sulodexide Inhibition of MMP-9 Gelatinase Secretion and Activity: Possible Pharmacological Role Against Collagen Degradation in Vascular Chronic Diseases, Current Vascular Pharmacology 2013; 11 (3) . https://dx.doi.org/10.2174/1570161111311030010
DOI https://dx.doi.org/10.2174/1570161111311030010 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ambroxol Chaperone Therapy for Gaucher Disease Type I-Associated Liver
Cirrhosis and Portal Hypertension: A Case Report
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuropeptides and Other Chemical Mediators, and the Role of Anti-inflammatory Drugs in Primary Headaches
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Brain local and regional neuroglial alterations in Alzheimer´s Disease: cell types, responses and implications.
Current Alzheimer Research Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Treatment of Disorders Characterized by Reversible Airway Obstruction in Childhood: are Anti-cholinergic Agents the Answer?
Current Pharmaceutical Design On the Sympathetic Innervation of the Human Greater Saphenous Vein: Relevance to Clinical Practice
Current Vascular Pharmacology Metal Complexes of Biologically Active Ligands as Potential Antioxidants
Current Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery Symptoms in Dilating Venous Disease
Current Cardiology Reviews Von Hippel-Lindau Disease
Current Molecular Medicine The Role of MDCT in Craniocervical Junction Pathologies: Pictorial Review
Current Medical Imaging The Significance of Pain in Chronic Venous Disease and its Medical Treatment
Current Vascular Pharmacology Radiological Diagnosis of Renal Thrombosis in Children
Current Pediatric Reviews Overview of Current Practice and Future Trends in Thromboprophylaxis for General Surgery
Vascular Disease Prevention (Discontinued) The Clinical Spectrum of Nephrogenic Systemic Fibrosis
Current Rheumatology Reviews Nummular Eczema: An Updated Review
Recent Patents on Inflammation & Allergy Drug Discovery Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management
Cardiovascular & Hematological Disorders-Drug Targets Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic Strategies
Medicinal Chemistry Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Alkannins and Shikonins: A New Class of Wound Healing Agents
Current Medicinal Chemistry